Silodosin is a highly selective α1A-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia...
Purpose: To evaluate the efficacy and safety of holmium laser enucleation of the prostate (HoLEP) for extremely large prostates. Materials...
To preliminary investigate the effects of silodosin 8 mg once daily on obstruction urodynamic parameters and subjective symptoms in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement.
The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including...
NxThera announced that new data from the first post-market clinical evaluation of its minimally invasive Rezu?m Radiofrequency System demonstrated significant,...
The progression of mild hyperkalemia and the predictors of progression have not been well characterized. In this study we aimed to characterize the progression of hyperkalemia and identify the risk factors for hyperkalemia progression.
Treatment of moderate to severe functional symptoms of benign prostatic hyperplasia (BPH).
Treatment of erectile dysfunction in adult males. In order for tadalafil to be effective, sexual stimulation is required. Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.
Teleflex Incorporated announced the full U.S. commercial launch of its UroLift 2 System and UroLift ATC System, and that it will update the urology community through multiple in-booth presentations at the 2022 American Urological Association (AUA) annual meeting. The conference will take place in-person from May 13-16 in New Orleans.
NxThera has announced the digital publication of the one-year data from the Rezum II pivotal study of the Rezum Radiofrequency...